|Day Low/High||100.56 / 102.30|
|52 Wk Low/High||61.61 / 102.89|
Next week the June quarter earnings season maelstrom kicks off with 115 companies, including 32 S&P 500 constituents, reporting their latest quarterly results. In recent days we've seen a number of companies up their outlook for the quarter but we'v...
I would wait until the next down day, and there will be one.
The current quarter, according to the analyst community, is understandably not shaping up as stellar.
I have always liked the aggressive management.
Don't pigeon hole yourself into a certain pattern of action when you see opportunities.
I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
CVS Health states that the chain has kept its stores open as an 'essential' retailer through this pandemic.
Oil isn't really worthless and Amazon isn't the only retailer that will survive, but we are in a mixed up market thanks to Covid-19.
Will tech continue to trend toward leadership? Who among us can remember when it has not?
Welcome to the new era. Social distancing is not without risks, but it is as good as it gets.
How has my book evolved since the Fed and Treasury rode into town? Here's how.
Although there is great fear of the economic issues that lie ahead, there is still a hunger for speculative action in the market.
These companies have the potential to help in battling the Covid-19 pandemic.
There will be some long-lasting changes in behavior that will impact the economy in many ways as it recovers.
Despite the dramatic and highly negative decline in economic activity that forced algos to hit the markets from above, enough portfolio managers faded that move to lessen its impact.
When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.
Tests, masks, contact tracing, anti-virals. Are those too much to ask?
I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.
As testing expands, drug trials proceed and tech greats are providing a tracking app, I think we're inching toward going back to work -- and further away from going so low again.
ABT is trading lower so far this Monday, and a pull back this week could allow traders a chance to buy weakness.
Most of the media continues to focus on the national response to the coronavirus.
Alhough a key chart shows a new high is possible, the stock of this enterprise software giant could be disappointng for a while.
I don't think it would be too much of a stretch to imagine that too many investors, or citizens for that matter, will mind seeing March 2020 head on out of here.
Now we need the gowns and masks from China to help fight this battle on the front lines.
Things will be different after Covid-19 and one change will be in how people care about themselves.
As it gets the OK for a new rapid Covid-19 detecting device, Abbott Labs could be purchased here following our new technical strategy.
I do believe that having no economy is temporary. I also believe that what comes out on the other side will be smaller, far less global.